NewAmsterdam Pha SEC Filings

namsw NASDAQ

Welcome to our dedicated page for NewAmsterdam Pha SEC filings (Ticker: namsw), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Clinical trial footnotes, milestone payments, and patent timelines in NewAmsterdam Pharma’s SEC filings can stretch well past 200 pages. If you’ve ever hunted for a single obicetrapib trial cost or wondered who bought warrants last quarter, you know the challenge. Our platform ends that search fatigue by turning dense disclosures into clear, actionable snapshots.

Stock Titan layers AI on every document the moment it hits EDGAR. Need the NewAmsterdam Pharma quarterly earnings report 10-Q filing distilled to cash-burn and Phase 3 spend? Want NewAmsterdam Pharma insider trading Form 4 transactions in real time? Prefer a one-page brief of the NewAmsterdam Pharma annual report 10-K simplified? We’ve got it. Our engine flags:

Form 4 updates—track NewAmsterdam Pharma executive stock transactions Form 4 minutes after insiders file.
10-K & 10-Q breakdowns—AI highlights R&D expense trends, trial enrolment data, and dilution risks.
8-K alerts—see NewAmsterdam Pharma 8-K material events explained, from BROADWAY topline results to new patents.
DEF 14A insight—quickly locate NewAmsterdam Pharma proxy statement executive compensation figures.

Whether you’re comparing lipid-lowering market opportunities or monitoring warrant conversions, our coverage delivers every form—10-K, 10-Q, 8-K, S-1, and more—complete with AI-powered plain-English summaries. Stop scrolling through footnotes; start understanding NewAmsterdam Pharma SEC documents with AI and perform deeper NewAmsterdam Pharma earnings report filing analysis in seconds.

06/26/2025 07:41 PM

Filing

[Form 4] NewAmsterdam Pharma Company N.V. Warrant Insider Trading Activity

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[Form 4] NewAmsterdam Pharma Company N.V. Warrant Insider Trading Activity

Rhea-AI Summary

Douglas F. Kling, Chief Operating Officer of NewAmsterdam Pharma, reported significant insider transactions on June 16, 2025:

Exercised stock options to acquire 100,000 total ordinary shares: - 78,101 shares at $10.00 per share - 21,899 shares at $10.90 per share
Subsequently sold 100,000 shares in two tranches: - 81,891 shares at weighted average price of $19.19 - 18,109 shares at weighted average price of $19.75
Post-transactions, Kling retains: - 44,000 ordinary shares - 372,829 options at $10.00 strike price - 261,314 options at $10.90 strike price

The transactions were executed under a Rule 10b5-1 trading plan. The sales represent a partial liquidation of Kling's holdings while maintaining significant equity exposure through remaining shares and options.

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

[Form 4] NewAmsterdam Pharma Company N.V. Warrant Insider Trading Activity

Rhea-AI Impact

Rhea-AI Sentiment

End-of-Day

-- %

FAQ

What is the current stock price of NewAmsterdam Pha (namsw)?

The current stock price of NewAmsterdam Pha (namsw) is $8.06 as of June 28, 2025.

What is NewAmsterdam Pharma's primary focus?

NewAmsterdam Pharma is dedicated to developing innovative, oral, non-statin therapies, with its lead candidate obicetrapib focused on lowering LDL cholesterol in patients with cardiovascular risk.

How does obicetrapib work?

Obicetrapib is a selective CETP inhibitor that reduces LDL cholesterol by modulating cholesterol transfer, and it has also shown beneficial effects on other lipid biomarkers significant for cardiovascular health.

What clinical programs are being conducted by NewAmsterdam?

The company is running several pivotal Phase 3 trials, including BROOKLYN, BROADWAY, TANDEM, and the cardiovascular outcomes PREVAIL trial, to evaluate obicetrapib as monotherapy and in combination with ezetimibe.

What differentiates obicetrapib from other LDL-C lowering therapies?

Obicetrapib offers a unique mechanism of action as a low-dose, once-daily, oral CETP inhibitor, providing efficacy in LDL-C reduction along with a favorable safety profile compared to traditional statin therapies.

How does NewAmsterdam protect its innovation?

The company has established a robust intellectual property portfolio, including recent patents that extend protection for obicetrapib until 2043, ensuring exclusivity in key markets.

What market needs does the company address?

NewAmsterdam aims to meet the significant unmet needs in LDL-C management among cardiovascular patients who do not achieve target levels with existing therapies, thereby addressing a critical gap in cardiovascular care.

Is the company planning global commercialization?

While the focus is currently on a comprehensive clinical evaluation, NewAmsterdam has made strategic preparations in manufacturing and operational readiness for a potential global launch, subject to regulatory approval.

How is NewAmsterdam Pharma's clinical trial data structured?

The clinical trials are carefully designed with multiple endpoints such as LDL-C reduction, safety assessments, and exploratory outcomes, ensuring a thorough evaluation of obicetrapib’s performance across a diverse patient population.